Cargando…
Chlorpromazine as a Potential Antipsychotic Choice in COVID-19 Treatment
Autores principales: | Muric, Nemanja N., Arsenijevic, Nebojsa N., Borovcanin, Milica M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785719/ https://www.ncbi.nlm.nih.gov/pubmed/33424669 http://dx.doi.org/10.3389/fpsyt.2020.612347 |
Ejemplares similares
-
Uric Acid Potential Role in Systemic Inflammation and Negative Symptoms After Acute Antipsychotic Treatment in Schizophrenia
por: Borovcanin, Milica M., et al.
Publicado: (2022) -
IL-33/ST2 Pathway and Galectin-3 as a New Analytes in Pathogenesis and Cardiometabolic Risk Evaluation in Psychosis
por: Borovcanin, Milica M., et al.
Publicado: (2018) -
Influence of antipsychotics on metabolic syndrome risk in patients with schizophrenia
por: Koricanac, Aleksandra, et al.
Publicado: (2022) -
Interleukin-6 in Schizophrenia—Is There a Therapeutic Relevance?
por: Borovcanin, Milica Milovan, et al.
Publicado: (2017) -
PM391. THE USE OF AMISULPRIDE IN TREATMENT OF PATIENTS WITH RESIDUAL SCHIZOPHRENIA
por: Janjic, Vladimir, et al.
Publicado: (2016)